Loading news...
Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating
Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst going forward. In my view, this is their make-or-break catalyst this year. A favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1.
Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Shares of Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) rose 7.4% on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as high as $4.46 and last traded at $4.3620. Approximately 634,615 shares
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
Corient Private Wealth LLC lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ: SANA) by 264.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,136,000 shares of the company's stock after acquiring an additional 824,505 shares during the
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology
Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
Sana (SANA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology.
Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and scalable administration, and massive funding needs before commercial viability is achieved.
Sana Biotechnology, Inc. (NASDAQ:SANA) shares soared on Wednesday after outspoken stock promoter Eric Jackson named it as his latest potential “100-bagger.”
Sana Biotechnology, Inc. (NASDAQ:SANA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Well, hello, everyone. I'm Maxwell Skor, biotech analyst with Morgan Stanley.